non-small cell lung cancer
In a new study, Dana Farber researchers and collaborators explain the myriad molecular reasons why KRAS-mutated cancers develop resistance to targeted therapy.
AstraZeneca, Hutchmed's Lung Cancer MET Inhibitor Approved in China
The NMPA approved the drug for non-small cell lung cancer patients who have progressed on prior therapy and have MET exon 14 skipping alterations.
Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer
The firm hopes its qPCR-based liquid biopsy test could help identify early-stage NSCLC patients eligible for adjuvant or neoadjuvant anti-EGFR TKI treatment.
Researchers used real-world data to identify low NGS testing rates, particularly among Black patients, suggesting many aren't getting precision medical treatment.
In IMpower010, Tecentriq significantly reduced the risk of death or disease recurrence in patients with stage II to IIIA tumors, particularly in those with PD-L1 expression.